AbbVie's Investigational DAA Regimen Receives Breakthrough Therapy Designation from US FDA
Cinnamon Girl said
May 7, 2013
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
- Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development -
May 6, 2013, NORTH CHICAGO, AbbVie today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA).
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
- Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development -
May 6, 2013, NORTH CHICAGO, AbbVie today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA).
Full article...
http://hcvadvocate.blogspot.ca/2013/05/abbvies-investigational-hcv-regimen.html